Steven Bellon
Chief Tech/Sci/R&D Officer bei FOGHORN THERAPEUTICS INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Steven F.
Bellon is currently the Chief Scientific Officer at Foghorn Therapeutics, Inc. He previously worked as the Executive Director & Head-Structural Biology at Constellation Pharmaceuticals, Inc. from 2008 to 2016.
Dr. Bellon holds a doctorate degree from the Massachusetts Institute of Technology, which he obtained in 1992.
He also has an undergraduate degree from Haverford College, which he received in 1987.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 29.02.2024 | 171 957 ( 0,40% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Steven Bellon
| Unternehmen | Position | Beginn |
|---|---|---|
| FOGHORN THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 10.01.2022 |
Ehemalige bekannte Positionen von Steven Bellon
| Unternehmen | Position | Ende |
|---|---|---|
| CONSTELLATION PHARMACEUTICALS, INC. | Director/Board Member | 01.05.2016 |
Ausbildung von Steven Bellon
| Massachusetts Institute of Technology | Doctorate Degree |
| Haverford College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| FOGHORN THERAPEUTICS INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
